Evidence map›Paper›PMID 39050866›Full record

ArticleClinical kidney journal2024

Elevated RHAMM as a biomarker for predicting diabetic kidney disease in patients with type 2 diabetes.

Bingxue Qi, Yan Lou, Yongyue Zhu, Yang Chen, Shixin Yang, Fanjie Meng, Zhuo Pan, Shuangshuang Liu, Guanchi Yan, Xiaodan Lu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical kidney journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bingxue QiDepartment of Nephrology, The Second Hospital of Jilin University, Changchun, China.
Yan LouDepartment of Nephrology, The Second Hospital of Jilin University, Changchun, China.
Yongyue ZhuClinical Medicine College, Changchun University of Chinese Medicine, Changchun, China.
Yang ChenClinical Medicine College, Changchun University of Chinese Medicine, Changchun, China.
Shixin YangDepartment of Endocrinology, Jilin Province People's Hospital, Changchun, China.
Fanjie MengDepartment of Endocrinology, Jilin Province People's Hospital, Changchun, China.
Zhuo PanPrecision Molecular Medicine Center, Jilin Province People's Hospital, Changchun, China.
Shuangshuang LiuShanghai Key Laboratory of Metabolic Remodeling and Health, Institute of Metabolism and Integrative Biology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Guanchi YanDepartment of Endocrinology, Affiliated Hospital to Changchun University of Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China.
Xiaodan LuPrecision Molecular Medicine Center, Jilin Province People's Hospital, Changchun, China.
Li-Hao HuangShanghai Key Laboratory of Metabolic Remodeling and Health, Institute of Metabolism and Integrative Biology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0002-9868-8709

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Diabetic kidney disease (DKD) poses a significant challenge globally as a complication of diabetes. Hyaluronan (HA), a critical non-sulfated glycosaminoglycan in the extracellular matrix, plays a pivotal role in the progression of DKD. This study assesses the predictive significance of HA's corresponding receptor, RHAMM (receptor for HA-mediated motility), in DKD pathogenesis in type 2 diabetes (T2DM) patients. Methods: Enzyme-linked immunosorbent assays were utilized to measure plasma and urine levels of HA, CD44 and RHAMM in 99 diabetic patients. Immunohistochemistry staining was employed to examine HA deposition, CD44 and RHAMM expressions from 18 biopsy-proven DKD patients. Spearman correlation analysis, linear regression and receiver operating characteristic (ROC) analysis were conducted to establish associations between plasma HA, CD44 and RHAMM levels, and clinical parameters in DKD patients with T2DM. Results: Elevated plasma and urine HA, CD44 and RHAMM levels were notably observed in the severe renal dysfunction group. Plasma RHAMM exhibited positive correlations with HA (r = 0.616, Conclusion: These findings provide initial evidence that elevated RHAMM levels predict DKD pathogenesis in T2DM patients. The formation of a triple complex involving HA, CD44 and RHAMM on the cell surface shows promise as a targetable biomarker for early intervention to mitigate severe renal dysfunctions.

Indexed as

biomarkerCD44diabetic kidney diseasehyaluronanRHAMMtype 2 diabetes

Identifiers

PMID39050866
PMCPMC11267228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.